ANTONIO FRANCESCO CAMPESE

CARI STUDENTI,

DI SEGUITO TROVERETE LE INFO UTILI PER SEGUIRE IN MODALITA' BLENDED LE MIE LEZIONI DEI VARI CORSI PER L'A.A. 2021-2022 / I SEMESTRE:

per qualsiasi dubbio, scrivete all'indirizzo antonello.campese@uniroma1.it

1) LINGUA INGLESE (CORSO INTEGRATO DI METODOLOGIA MEDICO-SCIENTIFICA INTEGRATA I) LAUREA IN MEDICINA E CHIRURGIA CCLM-D

ATTENZIONE: a seguito del rinvio dell'inizio delle lezioni LA PRIMA LEZIONE SARA' VENERDI' 08/10/2021 in modalità blended, come di seguito indicato

  - IN PRESENZA: ESCLUSIVAMENTE PER COLORO CHE SONO IN POSSESSO DI PRENOTAZIONE EFFETTUATA SECONDO LE LINEE GUIDA PER L'UTILIZZO DEL SISTEMA PRODIGIT, LE LEZIONI SI SVOLGERANNO IN AULA CATALDO CASSANO (CODICE EDIFICIO PL005 CODICE AULA E01PA1L001) A PARTIRE DA VENERDI' 08/10/20 ORE 17/20 E POI TUTTI I VENERDI' SECONDO L'ORARIO PUBBLICATO AL LINK https://corsidilaurea.uniroma1.it/it/node/2462129

 - DA REMOTO: LE LEZIONI SI SVOLGERANNO SULLA PIATTAFORMA ZOOM, CUI SARA' POSSIBILE ACCEDERE MEDIANTE INDIRIZZO ISTITUZIONALE.

IN DATA 280921 AI RAPPRESENTANTI DEL IV ANNO E' STATA INVIATA UNA MAIL CON L'INVITO  PER ACCEDERE ALLE LEZIONI E CHE RIMANE VALIDO PER TUTTO IL CORSO, CON PREGHIERA DI DIFFONDERLO A TUTTI GLI STUDENTI DEL CORSO.

-----------------------------------------------------------------------------------------------------------------------------------------

 2) Medicina molecolare e modelli animali di malattia/Medicina rigenerativa (indirizzo Biomolecolare)  MODULO CAMPESE - LAUREA MAGISTRALE IN BIOTECNOLOGIE MEDICHE

Cari Studenti, di seguito le indicazioni per seguire le lezioni

Le lezioni avranno inizio lunedì 04/10/2021 ore 14/16 in aula E di Ortopedia in modalità blended 

(Codice edificio CU035 Codice Aula E01PT013)

IN PRESENZA SOLO PER GLI STUDENTI IN POSSESSO DI REGOLARE PRENOTAZIONE E SEGUENDO LE ISTRUZIONI CHE SARANNO PRESTO PUBBLICATE SULLA SEZIONE FREQUENTARE DEL CORSO

DA REMOTO: LE LEZIONI SI SVOLGERANNO SULLA PIATTAFORMA ZOOM

IN DATA 280921 AI RAPPRESENTANTI DEL IV ANNO E' STATA INVIATA UNA MAIL CON L'INVITO  PER ACCEDERE ALLE LEZIONI E CHE RIMANE VALIDO PER TUTTO IL CORSO, CON PREGHIERA DI DIFFONDERLO A TUTTI GLI STUDENTI DEL CORSO.

-----------------------------------------------------------------------------------------------------------------------------------------

3) PRINCIPLES OF GENERAL PATHOLOGY - PROF. CAMPESE 

    BIOINFORMATICS

DEAR STUDENTS,

LESSONS WILL BE HELD EVERY FRIDAY, 8:30/11:00 AM, STARTING ON the 8th of october, 2021,

in a blended way:

- IN THE PRESENCE ONLY FOR THE STUDENT THAT HAVE BOOKED THE LESSONS for Classroom Psicologia II, Fisiologia Generale e Antropologia Farmacia e Medicina (CU026, E01PS1L084), through the PRODIGIT system

- TO ATTEND, INSTEAD, THE LESSONS ONLINE ON THE ZOOM PLATFORM PLEASE, COMPLETE YOUR SUBSCRIPTION TO THE COURSE ON THE E-LEARNING PLATFORM AT THE FOLLOWING ADDRESS https://elearning.uniroma1.it/enrol/index.php?id=6696

THERE, YOU WILL FIND THE LINK TO THE LESSONS!

ALTERNATIVELY, YOU CAN WRITE AN EMAIL TO antonello.campese@uniroma1.it 

Position Associate Professor (SSD MEDS-26/A)
Address/Affiliation Dept. of Molecular Medicine, Faculty of Pharmacy and Medicine,
'Sapienza' University of Rome.Viale Regina Elena , 291 - 00161, Roma, Italy

Education and training
1994 Master degree in Biology, 110/110 cum laude, Univ. ‘La Sapienza’, Rome; 2001 PhD in Experimental
Medicine, 4 years, Univ. of L’Aquila; 2001 Research fellow, 2 years, Project: ‘Role of HLH proteins in the
pathogenesis of lymphoproliferative diseases’, Dept. of Experimental Medicine and Pathology, Univ. ‘La
Sapienza’, Rome; 2002 Postgraduate Specialty School of Allergology and Clinic Immunology, 70/70 cum
laude, 4 years, Univ. ‘La Sapienza’, Rome; 2002 Research fellow, from 7/2002 to 12/2003, Project:
‘Molecular and cellular analysis of Notch3 and pTalpha interplay in leukemogenesis’, Harvard Medical
School, Dana Farber Cancer Institute, Dept. of Cancer, Immunology and AIDS, Prof. H. von Boehmer’s
Laboratory- Boston, MA, USA.

Academic Appointments
2004-2015 Researcher/Assistant Professor of General Pathology (SSD MED/04), ‘Sapienza’, Univ. of
Rome; 2009 Member of the panel of judges for the admission exam to the XXV cycle of the PhD Doctorate
School of Molecular Medicine, ‘Sapienza’, Univ. of Rome; 2013-present Member of the Teaching staff of
the PhD Doctorate School of Molecular Medicine, ‘Sapienza’, Univ. of Rome; 2014-2020 Elected member
of the Department Council ('Giunta di Dipartimento'), of the Department of Molecular Medicine, ‘Sapienza’,
Univ. of Rome; 2014-2020 Elected member of the Faculty Council ('Giunta di Facoltà') of the Faculty of
Pharmacy and Medicine, ‘Sapienza’, Univ. of Rome; 2015-present Scientific Member of the Animal
Welfare Committee (OPBA) of the Departments of Molecular Medicine and Experimental Medicine,
Sapienza, University of Rome; 2015 Member of the panel of judges for the final exam
of the XXVII cycle of the PhD Doctorate School of Experimental Medicine and Endocrinology, Univ. of
L'Aquila; 2015-present Associate Professor of Technical Sciences of Laboratory Medicine (SSD MED/46),
Department of Molecular Medicine, ‘Sapienza’, Univ. of Rome; 2016 Member of the panel of judges for the
admission exam to the XXXII cycle of the PhD Doctorate School of Molecular Medicine, ‘Sapienza’, Univ.
of Rome. 2020-present Affiliated Researcher of Fondazione IIT (Istituto Italiano di Tecnologia), 'Center for
Life Nano- & Neuro-Science' of Rome, Italy; 2021-present Participation as member of the Technical-
Scientific Commitee to the 'Centro di Ricerca e Servizi Sperimentazione Preclinica e Benessere Animale
(SPBA), ‘Sapienza’, Univ. of Rome; 2022-present Elected member of the Department Council ('Giunta di
Dipartimento'), of the Department of Molecular Medicine, ‘Sapienza’, Univ. of Rome; 2023-present Elected
member of the Faculty Council ('Giunta di Facoltà') of the Faculty of Pharmacy and Medicine, ‘Sapienza’,
Univ. of Rome; 2025 Member of the panel of judges for the admission exam to the XLI cycle of the PhD
Doctorate School of Molecular Medicine, ‘Sapienza’, Univ. of Rome. 2023 Achievement of the National
Scientific qualification as full professor in the Italian higher education system, in the call 2021/2023 for the
disciplinary field of 06/A2 -Experimental medicine, pathophysiology and clinical pathology. (Academic
Recruitment Field 06/A -Pathology and laboratory medicine, according to the national classification). The
validity of the qualification is twelve years, starting from the 17/12/2023 and will expire on the17/12/2035
2025 Achievement of the National Scientific qualification as full professor in the Italian higher education
system, in the call 2023/2025 for the disciplinary field of 06/N1 - Technology and methodology in medicine
and nursing sciences. (Academic Recruitment Field 06/N - Technology and methodology in medicine,
nursing and sport sciences, according to the national classification). The validity of the qualification is
twelve years, starting from the 14/03/2025 and will expire on the14/03/2037.

Teaching experience
A.Y. 2004/05-2016/17 Course of ‘General Pathophysiology’ for the Health Professions, Bachelor of Nursing
Science, ‘Sapienza’, University of Rome, CCL-Z Pomezia; A.Y. 2010/2011-2013/2014 Lectures of
‘Molecular Medicine and animal models of disease’, Master degree in Medical Biotechnology, ‘Sapienza’,
University of Rome; A.Y. 2014/15-present Course of ‘Molecular Medicine and animal models of disease’,
Master degree in Medical Biotechnology, ‘Sapienza’, University of Rome; A.Y. 2004/05-2014/15 Elective,
as part of the Course of ‘Pathology and General Physiopathology’, Master degree in Medicine and Surgery,
‘Sapienza’, University of Rome; A.Y. 2013/14-2017/18 Elective, as part of the Course of ‘Pathology and
General Physiopathology’, Master degree in Medicine and Surgery, International Medical School,
‘Sapienza’, University of Rome; A.Y. 2014/15-present Lectures of ‘Pathology’, as part of the Course of preclinical
Methodology I', Master degree in Medicine and Surgery, ‘Sapienza’, University of Rome; A.Y.
2017/18-present Course of ‘English Language’, Master degree in Medicine and Surgery, ‘Sapienza’,
University of Rome; A.Y. 2017/18-present Course of Technical Sciences of Laboratory Medicine, Bachelor
of Biomedical Laboratory Technics, AOS S.Camillo-Forlanini, ‘Sapienza’, University of Rome; A.Y.
2017/18-present Course of Technical Sciences of Laboratory Medicine I-II, Bachelor of Biomedical
Laboratory Technics, Pozzilli-Neuromed, ‘Sapienza’, University of Rome; A.Y.2018/19-present Course of
Diagnostic methods in Anatomical Pathology, Bachelor of Biomedical Laboratory Technics, Pozzilli-
Neuromed, ‘Sapienza’, University of Rome; A.Y.2018/19-present Course of in Diagnostic methods in
Clinical Pathology, Bachelor of Biomedical Laboratory Technics, Pozzilli-Neuromed, ‘Sapienza’, University
of Rome; A.Y. 2018/19-present Course of 'Principles of General Pathology', Bachelor of Bioinformatics (in
english language), 'Sapienza', Univ. di Roma; A.Y.2018/19-present Course of Advanced methods in
Laboratory Medicine, Bachelor of Biomedical Laboratory Technics, Pozzilli-Neuromed, ‘Sapienza’,
University of Rome; A.Y. 2020/2021-2024/2025 Participation as Tutor in the QuiD courses on 'Teaching
Innovation for RTD-Bs' , organized by the 'Gruppo per la Qualità e Innovazione della Didattica' (GdL-QuID,
D.R. n.2334 del 18/09/2017), Sapienza, University of Rome

Member of Editorial Board
2018-present Editorial Board Member of the International Journal of Molecular Sciences - Section of
Molecular Immunology, ISSN/eISSN:1422-0067
2017-2019 Guest Editor, Research Topic 'Notch Signaling as a Regulator of Tumor Immune Response';
Frontiers in Immunology, ISSN/eISSN: 1664-3224
2020-present Guest Editor, Special Issue 'T Cells and Innate Lymphoid Cells in the Immune Response
against Hematological Malignancies'; International Journal of Molecular Sciences, ISSN/eISSN:1422-0067
2022-present 'Associate Editor' of Frontiers in Immunology (eISSN: 1664-3224) and Frontiers in Oncology
(eISSN: 2234-943X) – Section of 'Cancer Immunity and Immunotherapy'.

Grants
1995 Grant of the ‘Consiglio Nazionale delle Ricerche’ for a post-graduate training at the Dept. of Human
Biopathology, I Faculty of Medicine and Surgery, University ‘La Sapienza’ of Rome; duration: from
01/03/1995 to 14/02/1996; 1996 Grant of the Foundation ‘Istituto Pasteur – Cenci Bolognetti’ for a post
graduate training at the Dept. of Human Biopathology, I Faculty of Medicine and Surgery, University ‘La
Sapienza’ of Rome; duration: 3 months; 2002 Grant of the ‘Italian Foundation for Cancer Research’ (FIRC),
entitled to ‘Leonino Fontana and Maria Lionello’ for oncology research abroad, at the Dana Farber Cancer
Institute, Harvard Medical School, Boston, MA, USA; duration: 1 year

Funding Information (main grants as PI)
2004 Code: 2004057781_003, ‘Role of NOTCH signalling in neural development and degeneration’ (PI of a
research unit), Italian Ministry of Education, Universities and Research (MIUR): ‘Programmi di Ricerca
Scientifica di Rilevante Interesse Nazionale’(PRIN); duration: 24 months (43.500 €); 2009 Code:
200937N3ME_005, ‘Identification of the susceptibility genes for familial medullary thyroid carcinoma in
RET mutation negative cases’, (PI of a research unit), Italian Ministry of Education, Universities and
Research (MIUR): ‘Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale’ (PRIN); duration: 24
months (from 17/10/2011 to 17/10/2013) (36.441 €); 2010 Code: C26A10MPAY, ‘Study of cellular and
molecular mechanisms involved in the generation and function of regulatory T cells’, ‘Sapienza’, University
of Rome: ‘Ricerche Universitarie’; duration: 12 months (31.500 €); 2011 Code: C26A115SP8, ‘Study of new
transcriptional interactions in the onset and progression of leukemia diseases’, Sapienza’, University of
Rome: ‘Ricerche Universitarie’; duration: 12 months (8.000 €); 2012 Code: C26A12BLM8. ‘Study of new
transcriptional interactions in the onset and progression of leukemia diseases', Sapienza’, University of
Rome: ‘Ricerche Universitarie’; duration: 12 months (7.000 €); 2014 Code: C26A14C2XA, ‘Role of the
interaction between Notch and NF-kappaB pathways in the development of leukemia disease with
lympho/myeloid features’, Sapienza’, University of Rome: ‘Ricerche Universitarie’; duration: 12 months
(5.000 €); 2015 Code: C26A15AR33, ‘Role of the interaction between Notch and NF-kappaB pathways in
the development of leukemia disease with lympho/myeloid features’, Sapienza’, University of Rome:
‘Ricerche Universitarie’; duration: 12 months (10.000 €); 2017 Code: RM11715C7C626BAB, ‘Role of the
Notch signaling pathway in the regulation of the tumor immune response: analysis of Myeloid Derived
Suppressor Cells in development and progression of the T-cell acute limphoblastic leukemia’, Sapienza’,
University of Rome: ‘Ricerche Universitarie’; duration: 12 months (10.000 €). 2021 Code:
RM12117A71419448, 'The influence of tumor microenvironment in the progression of Notch-dependent Tcell
acute lymphoblastic leukemia: exploring the role of the PD-1/PD-L1 axis'; Sapienza’, University of
Rome: 'Progetti di Ricerca 2021’; duration: 36 months (10.460 € + 23.787 € for one-year research grant).

Research interests
Main research interests are focused on the following topics, achieved mainly through the generation and
characterization of murine models:
1) Notch in T cell differentiation and in the development of ‘T-cell acute lymphoblastic leukemia’ (T-ALL).
Notch receptor family is deeply involved in both T cell differentiation and T cell leukemogenesis. We
demonstrated that transgenic mice, overexpressing the functional intracellular domain of Notch3 inside
thymocyte compartment (N3tg mice), develop an aggressive form of T cell leukemia/lymphoma, resembling
human T-ALL, that is sustained by the constitutive activation of NF-kappaB. Following research activities
(based on the generation and study of double mutant murine models on the N3tg background, as well as on
the analysis of human T-ALL cell lines and patients), were focused on the identification of molecular
mechanisms mediating Notch3 oncogenic role, in the final attempt to reveal innovative therapeutic strategies
for T-ALL disease. Among these mechanisms, we individuated:
- the interaction with pTalpha, the invariant chain of the immature preTCR complex; the genetic deletion of
pTalpha greatly reduced the development of leukemia; Notch3/pTalpha co-expression was also revealed as
peculiar of the active phase of the disease in human patients of T-ALL;
- the crosstalk with the PKC-theta pathway, as an important mediator in driving NF-kappaB activation;
- the alternative splicing of Ikaros, that cooperates with Notch in leading to the persistent activation of the
preTCR signaling;
- the acetylation of Notch3, that controls its stability and, thus its function in leukemia development;
- the induction of specific miRNAs that potentiate Notch signaling and sustain T-ALL progression;
2) Notch in the generation and function of regulatory T cells and in the pathogenesis of experimental
autoimmune diabetes.
Our starting observation was that Notch3 deregulation in T cell compartment of N3tg mice enhances the
generation and function of regulatory T cells, a subset of immunosuppressive cells, that are able to protect
these mice from the induction of experimental autoimmune diabetes. This peculiar role of Notch is sustained,
at least in part, by the activation of FoxP3, the master gene regulator of regulatory T cells. Following
research activities revealed that Notch-dependent induction of Foxp3 expression is mediated by the
interacion of Notch with both pTalpha/preTCR and canonical PKC-theta/NF-kappaB signaling pathways. In
another context, we also demonstrated that Jagged1, a specific Notch ligand, modulates the Notch-dependent
induction of regulatory T cells.
3) Notch in the crosstalk between leukemia cells and tumor microenvironment.
Recently, our interest is focused on the crosstalk between tumor cells and tumor microenvironment, in the
context of T-ALL development and progression. Using the murine models of Notch-dependent T-ALL
described above, we demonstrated the role of Notch pathway and the relevance of its interaction
with the p50/NF-kappaB signaling, in driving the expansion of 'Myeloid-derived suppressor cells' (MDSCs),
facilitating the disease progression, mainly through the inhibition of NK anti-cancer response. We are now
exploring the possibility to validate MDSCs as target of immunotherapy for both the cure of T-ALL and the
prevention of immune-related side effects, such as ICI-T1DM.

Publications
Prof. Campese is co-author of 50 indexed original articles published in peer reviewed International Journals
recorded in PubMed. He has a total H-index of 30 and 2630 total citations (Scopus, 06/10/2025).
- Pignataro C, Zoppoli P, Cappelli LV, Yoffe L, Moretti M, Izzo M, Mallia S, Kayembe C, Taylor A, Petrillo G, Affinito
A, Quintavalle C, De Luca G, Mascolo M, Verde S, Fraticelli A, Ciarrocchi A, Salerno P, De Smaele E, Campese AF,
Fragliasso V, Foà R, Merla G, Inghirami G, Condorelli G, Fiore D. BH3 mimetic drugs overcome the microenvironmentinduced
resistance to crizotinib in ALK+ anaplastic large cell lymphoma. Blood Adv. 2025 Oct 14;9(19):4757-4775. doi:
10.1182/bloodadvances.2024015322.
- Sergio I, Varricchio C, Squillante F, Cantale Aeo NM, Campese AF, Felli MP. Notch Inhibitors and BH3 Mimetics in
T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2024 Nov 29;25(23):12839. doi: 10.3390/ijms252312839.
- Abdollahzadeh B, Cantale Aeo NM, Giordano N, Orlando A, Basciani M, Peruzzi G, Grazioli P, Screpanti I, Felli MP,
Campese AF. The NF-κB1/p50 Subunit Influences the Notch/IL-6-Driven Expansion of Myeloid-Derived Suppressor
Cells in Murine T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2024 Sep 13;25(18):9882. doi:
10.3390/ijms25189882.
- Sergio I, Varricchio C, Patel SK, Del Gaizo M, Russo E, Orlando A, Peruzzi G, Ferrandino F, Tsaouli G, Coni S, Peluso
D, Besharat ZM, Campolo F, Venneri MA, Del Bufalo D, Lai S, Indraccolo S, Minuzzo S, La Starza R, Bernardini G,
Screpanti I, Campese AF, Felli MP. Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes
allowing maintenance and progression of T-ALL. Oncogene. 2024 Aug;43(34):2535-2547. doi: 10.1038/s41388-024-
03079-0.
- Baldini E, Cardarelli S, Campese AF, Lori E, Fallahi P, Virili C, Forte F, Pironi D, Di Matteo FM, Palumbo P, Costanzo
ML, D'Andrea V, Centanni M, Sorrenti S, Antonelli A, Ulisse S. Evaluation of the Therapeutic Effects of Harmine on
Anaplastic Thyroid Cancer Cells. Int J Mol Sci. 2024 Jan 17;25(2):1121. doi: 10.3390/ijms25021121.
- Grazioli P, Orlando A, Giordano N, Noce C, Peruzzi G, Abdollahzadeh B, Screpanti I, Campese AF. Notch-Signaling
Deregulation Induces Myeloid-Derived Suppressor Cells in T-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2022
Apr 4;13:809261. doi: 10.3389/fimmu.2022.809261.
- Fontanella RA, Sideri S, Di Stefano C, Catizone A, Di Agostino S, Angelini DF, Guerrera G, Battistini L,
Battafarano G, Del Fattore A, Campese AF, Padula F, De Cesaris P, Filippini A, Riccioli A. CD44v8-10 is a marker
for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells. Cancer Biol
Med. 2021 May 20:j.issn.2095-3941.2020.0495. doi: 10.20892/j.issn.2095-3941.2020.0495.
- Grazioli P, Orlando A, Giordano N, Noce C, Peruzzi G, Scafetta G, Screpanti I, Campese AF. NF-κB1 Regulates
Immune Environment and Outcome of Notch-Dependent T-Cell Acute Lymphoblastic Leukemia. Front Immunol.
2020 Apr 3;11:541. doi: 10.3389/fimmu.2020.00541.
- Perli E, Pisano A, Pignataro MG, Campese AF, Pelullo M, Genovese I, de Turris V, Ghelli AM, Cerbelli B,
Giordano C, Colotti G, Morea V, d'Amati G. Exogenous peptides are able to penetrate human cell and mitochondrial
membranes, stabilize mitochondrial tRNA structures, and rescue severe mitochondrial defects. FASEB J. 2020
Jun;34(6):7675-7686. doi: 10.1096/fj.201903270R.
- Ferrandino F, Grazioli P, Bellavia D, Campese AF, Screpanti I, Felli MP. Notch and NF-κB: Coach and Players of
Regulatory T-Cell Response in Cancer. Front Immunol. 2018 Oct 11;9:2165. doi: 10.3389/fimmu.2018.02165. Review.
- Di Stefano C, Grazioli P, Fontanella RA, De Cesaris P, D'Amore A, Regno M, Starace D, Padula F, Fiori ME,
Canipari R, Stoppacciaro A, Pesce M, Filippini A*, Campese AF*, Ziparo E, Riccioli A. Stem-like and highly
invasive prostate cancer cells expressing CD44v8-10 marker originate from CD44-negative cells. Oncotarget. 2018 Jul
20;9(56):30905-30918. doi: 10.18632/oncotarget.25773. *co-corresponding author
- Ferrandino F, Bernardini G, Tsaouli G, Grazioli P, Campese AF, Noce C, Ciuffetta A, Vacca A, Besharat ZM,
Bellavia D, Screpanti I, Felli MP. Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia
propagation. Oncogene. 2018 Dec;37(49):6285-6298. doi: 10.1038/s41388-018-0401-2.
- Di Ianni M, Baldoni S, Del Papa B, Aureli P, Dorillo E, De Falco F, Albi E, Varasano E, Di Tommaso A, Giancola
R, Accorsi P, Rotta G, Rompietti C, Silva Barcelos EC, Campese AF, Di Bartolomeo P, Screpanti I, Rosati E, Falzetti
F, Sportoletti P. NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells.
Front Oncol. 2018 Apr 20;8:105. doi: 10.3389/fonc.2018.00105.
- Porciello N, Grazioli P, Campese AF, Kunkl M, Caristi S, Mastrogiovanni M, Muscolini M, Spadaro F, Favre C,
Nunès JA, Borroto A, Alarcon B, Screpanti I, Tuosto L. A non-conserved amino acid variant regulates differential
signalling between human and mouse CD28. Nat Commun. 2018 Mar 14;9(1):1080. doi:10.1038/s41467-018-03385-8.
- Grazioli P, Felli MP, Screpanti I, Campese AF*. The mazy case of Notch and immunoregulatory cells. J Leukoc
Biol. 2017 Aug;102(2):361-368. doi:10.1189/jlb.1VMR1216-505R. *co-corresponding author Review IF 4.224
- Franciosa G, Diluvio G, Gaudio FD, Giuli MV, Palermo R, Grazioli P, Campese AF, Talora C, Bellavia D,
D'Amati G, Besharat ZM, Nicoletti C, Siebel CW, Choy L, Rustighi A, Sal GD, Screpanti I, Checquolo S. Prolylisomerase
Pin1 controls Notch3 protein expression and regulates T-ALL progression. Oncogene. 2016 Sep 8;35(36):4741-51. doi:
10.1038/onc.2016.5.
- Perli E, Fiorillo A, Giordano C, Pisano A, Montanari A, Grazioli P, Campese AF, Di Micco P, Tuppen HA,
Genovese I, Poser E, Preziuso C, Taylor RW, Morea V, Colotti G, d'Amati G. Short peptides from leucyl-tRNA
synthetase rescue disease-causing mitochondrial tRNA point mutations. Hum Mol Genet. 2016 Mar 1;25(5):903-15.
doi: 10.1093/hmg/ddv619.
- Verginelli F, Adesso L, Limon I, Alisi A, Gueguen M, Panera N, Giorda E, Raimondi L, Ciarapica R, Campese
AF, Screpanti I, Stifani S, Kitajewski J, Miele L, Rota R, Locatelli F. Activation of an endothelial Notch1-Jagged1
circuit induces VCAM1 expression, an effect amplified by interleukin-1β. Oncotarget. 2015 Dec 22;6(41):43216-29.
doi: 10.18632/oncotarget.6456
- Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, Campese AF, Maresca A, Montopoli M, Masuelli L,
Sadun AA, d'Amati G, Carelli V, Ghelli A, Giordano C. Targeting estrogen receptor β as preventive therapeutic
strategy for Leber's hereditary optic neuropathy. Hum Mol Genet. 2015 Dec 15;24(24):6921-31. doi:
10.1093/hmg/ddv396.
- Anastasiadou E, Garg N, Bigi R, Yadav S, Campese AF, Lapenta C, Spada M, Cuomo L, Botta A, Belardelli F,
Frati L, Ferretti E, Faggioni A, Trivedi P. Epstein-Barr virus infection induces miR-21 in terminally differentiated
malignant B cells. Int J Cancer. 2015 Sep 15;137(6):1491-7. doi: 10.1002/ijc.29489.
- Kumar V, Palermo R, Talora C, Campese AF, Checquolo S, Bellavia D, Tottone L, Testa G, Miele E, Indraccolo
S, Amadori A, Ferretti E, Gulino A, Vacca A, Screpanti I. Notch and NF-kB signaling pathways regulate miR-
223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia. 2014 Dec;28(12):2324-35. doi:
10.1038/leu.2014.133.
- Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A,
Lacroix L, Russo D, Filetti S, Damante G. Overexpression of genes involved in miRNA biogenesis in medullary
thyroid carcinomas with RET mutation. Endocrine. 2014 Nov;47(2):528-36. doi: 10.1007/s12020-014-0204-3.
- Cipriani P, Di Benedetto P, Ruscitti P, Campese AF, Liakouli V, Carubbi F, Pantano I, Berardicurt O, Screpanti I,
Giacomelli R. Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular
and fibrotic features. Arthritis Res Ther. 2014 Sep 24;16(5):442. doi: 10.1186/s13075-014-0442-z.
- Campese AF*, Grazioli P*, de Cesaris P*, Riccioli A, Bellavia D, Pelullo M, Padula F, Noce C, Verkhovskaia S,
Filippini A, Latella G, Screpanti I, Ziparo E, Starace D. Mouse Sertoli cells sustain de novo generation of regulatory T
cells by triggering the notch pathway through soluble JAGGED1. Biol Reprod. 2014 Mar 13;90(3):53. doi:
10.1095/biolreprod.113.113803. *equally contributor.
- Germani A, Matrone A, Grossi V, Peserico A, Sanese P, Liuzzi M, Palermo R, Murzilli S, Campese AF, Ingravallo
G, Canettieri G, Tezil T, Simone C. Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α
modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Lett. 2014 Mar
1;344(1):110-8. doi: 10.1016/j.canlet.2013.10.035.
- Perli E, Giordano C, Pisano A, Montanari A, Campese AF, Reyes A, Ghezzi D, Nasca A, Tuppen HA, Orlandi M,
Di Micco P, Poser E, Taylor RW, Colotti G, Francisci S, Morea V, Frontali L, Zeviani M, d'Amati G. The isolated
carboxy-terminal domain of human mitochondrial leucyl-tRNA synthetase rescues the pathological phenotype of
mitochondrial tRNA mutations in human cells. EMBO Mol Med. 2014 Feb;6(2):169-82. doi:
10.1002/emmm.201303198.
- Garg N, Po A, Miele E, Campese AF, Begalli F, Silvano M, Infante P, Capalbo C, De Smaele E, Canettieri G, Di
Marcotullio L, Screpanti I, Ferretti E, Gulino A. microRNA-17-92 cluster is a direct Nanog target and controls neural
stem cell through Trp53inp1. EMBO J. 2013 Oct 30;32(21):2819-32. doi: 10.1038/emboj.2013.214.
- Cipriani P, Marrelli A, Benedetto PD, Liakouli V, Carubbi F, Ruscitti P, Alvaro S, Pantano I, Campese AF,
Grazioli P, Screpanti I, Giacomelli R. Scleroderma Mesenchymal Stem Cells display a different phenotype from
healthy controls; implications for regenerative medicine. Angiogenesis. 2013 Jul;16(3):595-607. doi: 10.1007/s10456-
013-9338-9.
- Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, Severa M, Coccia EM, Bigi R, Cirone M,
Ferretti E, Campese AF, Hummel M, Frati L, Presutti C, Faggioni A, Trivedi P. Differential regulation of miR-21 and
miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia. 2012 Nov;26(11):2343-52. doi: 10.1038/leu.2012.108.
- Palermo R, Checquolo S, Giovenco A, Grazioli P, Kumar V, Campese AF, Giorgi A, Napolitano M, Canettieri G,
Ferrara G, Schininà ME, Maroder M, Frati L, Gulino A, Vacca A, Screpanti I. Acetylation controls Notch3 stability
and function in T-cell leukemia. Oncogene. 2012 Aug 16;31(33):3807-17. doi: 10.1038/onc.2011.533.
- Perli E, Giordano C, Tuppen HA, Montopoli M, Montanari A, Orlandi M, Pisano A, Catanzaro D, Caparrotta L,
Musumeci B, Autore C, Morea V, Di Micco P, Campese AF, Leopizzi M, Gallo P, Francisci S, Frontali L, Taylor
RW, d'Amati G. Isoleucyl-tRNA synthetase levels modulate the penetrance of a homoplasmic m.4277T>C
mitochondrial tRNA(Ile) mutation causing hypertrophic cardiomyopathy. Hum Mol Genet. 2012 Jan 1;21(1):85-100.
doi: 10.1093/hmg/ddr440.
- Barbarulo A, Grazioli P, Campese AF, Bellavia D, Di Mario G, Pelullo M, Ciuffetta A, Colantoni S, Vacca A,
Frati L, Gulino A, Felli MP, Screpanti I. Notch3 and canonical NFkappaB signaling pathways cooperatively regulate
Foxp3 transcription. J Immunol. 2011 Jun 1;186(11):6199-206. doi: 10.4049/jimmunol.1002136.
- Giannini E, Lattanzi R, Nicotra A, Campese AF, Grazioli P, Screpanti I, Balboni G, Salvadori S, Sacerdote P,
Negri L. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory
pain. Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14646-51. doi: 10.1073/pnas.0903720106.
- Campese AF, Grazioli P, Colantoni S, Anastasi E, Mecarozzi M, Checquolo S, De Luca G, Bellavia D, Frati L,
Gulino A, Screpanti I. Notch3 and pTalpha/pre-TCR sustain the in vivo function of naturally occurring regulatory T
cells. Int Immunol. 2009 Jun;21(6):727-43. doi: 10.1093/intimm/dxp042.
- Talora C, Campese AF, Bellavia D, Felli MP, Vacca A, Gulino A, Screpanti I. Notch signaling and diseases: an
evolutionary journey from a simple beginning to complex outcomes. Biochim Biophys Acta. 2008 Sep;1782(9):489-
97. doi:10.1016/j.bbadis.2008.06.008. Review.
- Bellavia D, Checquolo S, Campese AF, Felli MP, Gulino A, Screpanti I. Notch3: from subtle structural differences
to functional diversity. Oncogene. 2008 Sep 1;27(38):5092-8. doi: 10.1038/onc.2008.230. Review.
- Bellavia D, Mecarozzi M, Campese AF, Grazioli P, Talora C, Frati L, Gulino A, Screpanti I. Notch3 and the
Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO J. 2007 Mar 21;26(6):1670-
80.
- Bellavia D, Mecarozzi M, Campese AF, Grazioli P, Gulino A, Screpanti I. Notch and Ikaros: not only converging
players in T cell leukemia. Cell Cycle. 2007 Nov 15;6(22):2730-4. Review.
- Tacconelli A, Farina AR, Cappabianca L, Cea G, Panella S, Chioda A, Gallo R, Cinque B, Sferra R, Vetuschi A,
Campese AF, Screpanti I, Gulino A, Mackay AR. TrkAIII expression in the thymus. J Neuroimmunol. 2007
Feb;183(1-2):151-61.
- Campese AF, Garbe AI, Zhang F, Grassi F, Screpanti I, von Boehmer H. Notch1-dependent lymphomagenesis is
assisted by but does not essentially require pre-TCR signaling. Blood. 2006 Jul 1;108(1):305-10.
- Felli MP, Vacca A, Calce A, Bellavia D, Campese AF, Grillo R, Di Giovine M, Checquolo S, Talora C, Palermo
R, Di Mario G, Frati L, Gulino A, Screpanti I. PKC theta mediates pre-TCR signaling and contributes to Notch3-
induced T-cell leukemia. Oncogene. 2005 Feb3;24(6):992-1000. PubMed PMID: 15592506.
- Talora C, Campese AF, Bellavia D, Pascucci M, Checquolo S, Groppioni M, Frati L, von Boehmer H, Gulino A,
Screpanti I. Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell
lymphoma. EMBO Rep. 2003 Nov;4(11):1067-72.
- Anastasi E*, Campese AF*, Bellavia D, Bulotta A, Balestri A, Pascucci M, Checquolo S, Gradini R, Lendahl U,
Frati L, Gulino A, Di Mario U, Screpanti I. Expression of activated Notch3 in transgenic mice enhances generation of
T regulatory cells and protects against experimental autoimmune diabetes. J Immunol. 2003 Nov 1;171(9):4504-11.
*equally contributor.
- Campese AF, Bellavia D, Gulino A, Screpanti I. Notch signalling at the crossroads of Tcell development and
leukemogenesis. Semin Cell Dev Biol. 2003 Apr;14(2):151-7. Review.
- Screpanti I, Bellavia D, Campese AF, Frati L, Gulino A. Notch, a unifying target in T-cell acute lymphoblastic
leukemia? Trends Mol Med. 2003 Jan;9(1):30-5. Review.
- Bellavia D, Campese AF, Vacca A, Gulino A, Screpanti I. Notch3, another Notch in T cell development. Semin
Immunol. 2003 Apr;15(2):107-12. Review
- Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A, Cazzaniga G, Lendahl U, Fehling HJ, Hayday AC,
Frati L, von Boehmer H, Gulino A, Screpanti I. Combined expression of pTalpha and Notch3 in T cell leukemia
identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93.
- Bellavia D*, Campese AF*, Alesse E, Vacca A, Felli MP, Balestri A, Stoppacciaro A, Tiveron C, Tatangelo L,
Giovarelli M, Gaetano C, Ruco L, Hoffman ES, Hayday AC, Lendahl U, Frati L, Gulino A, Screpanti I. Constitutive
activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J. 2000 Jul 3;19(13):3337-
48. *equally contributor.
- Felli MP, Maroder M, Mitsiadis TA, Campese AF, Bellavia D, Vacca A, Mann RS, Frati L, Lendahl U, Gulino A,
Screpanti I. Expression pattern of notch1, 2 and 3 and Jagged1 and 2 in lymphoid and stromal thymus components:
distinct ligand-receptor interactions in intrathymic T cell development. Int Immunol. 1999 Jul;11(7):1017-25.
- Simeoni L, Forte P, Aiuti A, Candido A, Campese AF, Fedele G, Di Tommaso F, Navarra M, Fantoni A.
Transgenic mice expressing human HIV receptors become persistently recipient of HIV DNA after injection with
infected human cell lines. Folia Microbiol (Praha). 1998;43(5):525-6.